Taofeek K. Owonikoko
Emory University
CancerInternal medicineSurgeryPathologyOncologyImmunologyLung cancerChemotherapyImmunotherapyLungCarboplatinNon small cellIn patientPhases of clinical researchCancer researchRadiation therapyClinical trialMedicineBiologyPharmacology
Publications 457
#3T. Stinchcombe (Duke University)H-Index: 4
#8T A Ritter (VA: United States Department of Veterans Affairs)
Clinical outcomes for limited stage small cell lung cancer (LS-SCLC) remain suboptimal. Standard of care chemoradiation with platinum/etoposide and thoracic radiation to 45 Gy delivered twice daily followed by prophylactic cranial irradiation yields a median overall survival of 30 months. LU005 is a randomized phase II/III trial designed to test the addition of atezolizumab to concurrent chemoradiation. Patients with LS-SCLC (Tx-T4, N0-N3, M0) are randomly assigned in a 1:1 ratio to either stand...
Purpose/Objective(s) null Biology-guided radiotherapy (BgRT) is a new radiation modality that utilizes real-time limited time sampled FDG PET images of a tumor to deliver a dynamically tracked dose distribution. Since the delivered radiotherapy dose is dependent on the FDG distribution at each fraction, the ability to deliver the planned dose despite variations in daily FDG signal must be established. This study evaluates the predicted dose distribution for BgRT based on serial FDG scans obtaine...
#1Rebecca C. Obeng (NU: Northwestern University)H-Index: 9
#2V. Parihar (Emory University)
Last. Rafi Ahmed (Emory University)H-Index: 159
view all 9 authors...
#1Zhen Chen (Emory University)H-Index: 2
#2Danlei Yu (Emory University)H-Index: 1
Last. Shi-Yong Sun (Emory University)H-Index: 71
view all 5 authors...
Emergence of acquired resistance to osimertinib (AZD9291), the first-approved third-generation EGFR inhibitor that selectively and irreversibly inhibits the activating EGFR mutations and the resistant T790M mutation, is a giant and urgent clinical challenge. Fully understanding the biology underlying the response of EGFR mutant non-small cell lung cancer (NSCLC) to osimertinib is the foundation for development of mechanism-driven strategies to overcome acquired resistance to osimertinib or other...
#1Xiulei Mo (Emory University)H-Index: 12
#2Qiankun Niu (Emory University)H-Index: 7
Last. Haian Fu (Emory University)H-Index: 61
view all 22 authors...
Comprehensive sequencing of patient tumors reveals numerous genomic mutations across tumor types that enable tumorigenesis and progression. A subset of oncogenic driver mutations results in neomorphic activity where the mutant protein mediates functions not engaged by the parental molecule. Here, we identify prevalent variant-enabled neomorph-protein-protein interactions (neoPPI) with a quantitative High Throughput differential Screening (qHT-dS) platform. Coupling of highly sensitive BRET biose...
#1Sibo Tian (Emory University)H-Index: 21
#2B. Kazzi (Emory University)
Last. Taofeek K. Owonikoko (Emory University)H-Index: 61
view all 13 authors...
#1Millie Das (VA Palo Alto Healthcare System)H-Index: 12
#2Sukhmani K. Padda (Cedars-Sinai Medical Center)
Last. Taofeek K. Owonikoko (Emory University)H-Index: 61
view all 4 authors...
Second-line treatment options for patients with relapsed, extensive-stage small cell lung cancer (ES-SCLC) are limited, and even with currently available treatments, prognosis remains poor. Until recently, topotecan (a topoisomerase I inhibitor) was the only drug approved by the United States (US) Food and Drug Administration (FDA) for the management of ES-SCLC following progression after first-line treatment with etoposide plus a platinum derivative (EP; carboplatin preferred). With the most re...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.